Drug Profile
AlloCSC 02
Alternative Names: AlloCSC-02; Allogenic Cardiac Stem Cells - TiGenixLatest Information Update: 03 Aug 2018
Price :
$50
*
At a glance
- Originator Coretherapix
- Developer TiGenix
- Class Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cardiomyopathies